Polydeoxyribonucleotide Dermal Infiltration in Male Genital Lichen Sclerosus: Adjuvant Effects during Topical Therapy
Background. Lichen sclerosus (LS) is an autoimmune inflammatory skin disease that leads to tissue sclerosis. Actually, the first-line treatment consists of local steroid as clobetasol propionate (CP). Polydeoxyribonucleotide (PDRN) has demonstrated anti-inflammatory effects through the reduction of...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Dermatology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2013/654079 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545737587556352 |
|---|---|
| author | Luigi Laino Silvia Suetti Isabella Sperduti |
| author_facet | Luigi Laino Silvia Suetti Isabella Sperduti |
| author_sort | Luigi Laino |
| collection | DOAJ |
| description | Background. Lichen sclerosus (LS) is an autoimmune inflammatory skin disease that leads to tissue sclerosis. Actually, the first-line treatment consists of local steroid as clobetasol propionate (CP). Polydeoxyribonucleotide (PDRN) has demonstrated anti-inflammatory effects through the reduction of cytokine production and growth stimulation of fibroblast. Objective. To evaluate the efficacy of intradermal administration of PDRN in male patients suffering from genital lichen sclerosus in addition to topical 0.05% CP, as compared to administering 0.05% CP without PDRN injection. Patients/Methods. A group of male patients (n = 28; aged 25 to 65) suffering from LS were observed during topical therapy or subdermal in addition to topical therapy. Disease activity at baseline was evaluated on Investigator’s Global Assessment (IGA) and the Dermatology Life Quality Index (DLQI). We used polydeoxyribonucleotide in a commercial preparation for human use and a topical CP emulsion. Results. After therapy, in all group A patients there has been a regression of most of clinical pathological signs, while there has been a moderate improvement in all group B patients. Conclusions. On site intradermal administration of PDRN, associated with CP 0.05% cream, seemed to be associated with a clinical improvement of lichen sclerosus better than CP used in single therapy. |
| format | Article |
| id | doaj-art-c1b4ab55cb7049e1a8a06582c510715e |
| institution | Kabale University |
| issn | 1687-6105 1687-6113 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Dermatology Research and Practice |
| spelling | doaj-art-c1b4ab55cb7049e1a8a06582c510715e2025-02-03T07:24:49ZengWileyDermatology Research and Practice1687-61051687-61132013-01-01201310.1155/2013/654079654079Polydeoxyribonucleotide Dermal Infiltration in Male Genital Lichen Sclerosus: Adjuvant Effects during Topical TherapyLuigi Laino0Silvia Suetti1Isabella Sperduti2Dermatology and Venereology Center, Via Bixio 95, 00185 Rome, ItalyDermatology and Venereology Center, Via Bixio 95, 00185 Rome, ItalyRegina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyBackground. Lichen sclerosus (LS) is an autoimmune inflammatory skin disease that leads to tissue sclerosis. Actually, the first-line treatment consists of local steroid as clobetasol propionate (CP). Polydeoxyribonucleotide (PDRN) has demonstrated anti-inflammatory effects through the reduction of cytokine production and growth stimulation of fibroblast. Objective. To evaluate the efficacy of intradermal administration of PDRN in male patients suffering from genital lichen sclerosus in addition to topical 0.05% CP, as compared to administering 0.05% CP without PDRN injection. Patients/Methods. A group of male patients (n = 28; aged 25 to 65) suffering from LS were observed during topical therapy or subdermal in addition to topical therapy. Disease activity at baseline was evaluated on Investigator’s Global Assessment (IGA) and the Dermatology Life Quality Index (DLQI). We used polydeoxyribonucleotide in a commercial preparation for human use and a topical CP emulsion. Results. After therapy, in all group A patients there has been a regression of most of clinical pathological signs, while there has been a moderate improvement in all group B patients. Conclusions. On site intradermal administration of PDRN, associated with CP 0.05% cream, seemed to be associated with a clinical improvement of lichen sclerosus better than CP used in single therapy.http://dx.doi.org/10.1155/2013/654079 |
| spellingShingle | Luigi Laino Silvia Suetti Isabella Sperduti Polydeoxyribonucleotide Dermal Infiltration in Male Genital Lichen Sclerosus: Adjuvant Effects during Topical Therapy Dermatology Research and Practice |
| title | Polydeoxyribonucleotide Dermal Infiltration in Male Genital Lichen Sclerosus: Adjuvant Effects during Topical Therapy |
| title_full | Polydeoxyribonucleotide Dermal Infiltration in Male Genital Lichen Sclerosus: Adjuvant Effects during Topical Therapy |
| title_fullStr | Polydeoxyribonucleotide Dermal Infiltration in Male Genital Lichen Sclerosus: Adjuvant Effects during Topical Therapy |
| title_full_unstemmed | Polydeoxyribonucleotide Dermal Infiltration in Male Genital Lichen Sclerosus: Adjuvant Effects during Topical Therapy |
| title_short | Polydeoxyribonucleotide Dermal Infiltration in Male Genital Lichen Sclerosus: Adjuvant Effects during Topical Therapy |
| title_sort | polydeoxyribonucleotide dermal infiltration in male genital lichen sclerosus adjuvant effects during topical therapy |
| url | http://dx.doi.org/10.1155/2013/654079 |
| work_keys_str_mv | AT luigilaino polydeoxyribonucleotidedermalinfiltrationinmalegenitallichensclerosusadjuvanteffectsduringtopicaltherapy AT silviasuetti polydeoxyribonucleotidedermalinfiltrationinmalegenitallichensclerosusadjuvanteffectsduringtopicaltherapy AT isabellasperduti polydeoxyribonucleotidedermalinfiltrationinmalegenitallichensclerosusadjuvanteffectsduringtopicaltherapy |